Patents Assigned to Akebia Therapeutics Inc.
-
Patent number: 11883386Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.Type: GrantFiled: July 27, 2022Date of Patent: January 30, 2024Assignee: Akebia Therapeutics, Inc.Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D Greis, Angelique Sun Boyer, Namal C. Warshakoon
-
Patent number: 11857543Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.Type: GrantFiled: June 4, 2014Date of Patent: January 2, 2024Assignee: Akebia Therapeutics, Inc.Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
-
Patent number: 11844756Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.Type: GrantFiled: April 4, 2022Date of Patent: December 19, 2023Assignee: Akebia Therapeutics, Inc.Inventors: Alexander Smith, Gurudatt Ajay Chandorkar, Ene Ikpong Ette, Bradley John Maroni, Charlotte Suzanne Hartman, Ramin Farzaneh-Far, Jula Kern Inrig
-
Publication number: 20230295110Abstract: The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).Type: ApplicationFiled: August 13, 2021Publication date: September 21, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Thomas P. BLAISDELL, Senkara Rao ALLU, Paul E. FLEMING
-
Publication number: 20230286918Abstract: Disclosed herein are methods and processes of preparing vadadustat or a pharmaceutically acceptable salts thereof, and intermediates (e.g., a compound of Formula (I), (I-F), (II), or (IV), or a pharmaceutically acceptable salts thereof) useful for the synthesis of vadadustat.Type: ApplicationFiled: July 1, 2021Publication date: September 14, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Valdas JURKAUSKAS, Young Chun JUNG, Taesoo KWON, Arunachalam KANNAN, Vijaya Bhasker GONDI
-
Publication number: 20230285374Abstract: This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.Type: ApplicationFiled: October 29, 2020Publication date: September 14, 2023Applicants: Akebia Therapeutics, Inc., Mitsubishi Tanabe Pharma CorporationInventors: Emil deGoma, Nobuko Maruyama, Genki Kaneko
-
Publication number: 20230263786Abstract: Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.Type: ApplicationFiled: June 17, 2021Publication date: August 24, 2023Applicants: Akebia Therapeutics, Inc., Mitsubishi Tanabe Pharma CorporationInventors: Ajit CHAVAN, Rishikesh SAWANT, Yoshimasa KOKADO, Takehiro NANJO, Shuji KINOSHITA, Naomi KONISHI
-
Patent number: 11713298Abstract: Disclosed herein are methods and processes of preparing vadadustat and pharmaceutically acceptable salts thereof, and intermediates of formula (I) and their salts useful for the synthesis of vadadustat.Type: GrantFiled: May 8, 2019Date of Patent: August 1, 2023Assignee: Akebia Therapeutics, Inc.Inventors: Boris I. Gorin, Christopher M. Lanthier, Anne Buu Chau Luong, James Densmore Copp, Javier Gonzalez
-
Publication number: 20230227426Abstract: The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.Type: ApplicationFiled: March 19, 2021Publication date: July 20, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Paul E. FLEMING, Thomas P. BLAISDELL, Senkara Rao ALLU
-
Publication number: 20230218592Abstract: Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.Type: ApplicationFiled: April 20, 2021Publication date: July 13, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Steven BURKE, Michael RABINOWITZ
-
Publication number: 20230212138Abstract: The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.Type: ApplicationFiled: March 19, 2021Publication date: July 6, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Paul E. FLEMING, Thomas P. BLAISDELL, Senkara Rao ALLU
-
Patent number: 11690836Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.Type: GrantFiled: June 15, 2021Date of Patent: July 4, 2023Assignee: AKEBIA THERAPEUTICS, INC.Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
-
Publication number: 20230159489Abstract: The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.Type: ApplicationFiled: March 19, 2021Publication date: May 25, 2023Applicant: Akebia Therapeutics, Inc.Inventors: Paul E. FLEMING, Thomas P. BLAISDELL, Senkara Rao ALLU
-
Patent number: 11524939Abstract: Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof.Type: GrantFiled: November 12, 2020Date of Patent: December 13, 2022Assignee: Akebia Therapeutics, Inc.Inventors: Sudhir Ranjan, Xiaoyang Wang
-
Patent number: 11426393Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.Type: GrantFiled: June 22, 2020Date of Patent: August 30, 2022Assignee: Akebia Therapeutics, Inc.Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Namal C. Warshakoon
-
Patent number: 11324734Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.Type: GrantFiled: March 31, 2016Date of Patent: May 10, 2022Assignee: Akebia Therapeutics, Inc.Inventors: Alexander Smith, Gurudatt Ajay Chandorkar, Ene Ikpong Ette, Bradley John Maroni, Charlotte Suzanne Hartman, Ramin Farzaneh-Far, Jula Kern Inrig
-
Patent number: 11267785Abstract: Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.Type: GrantFiled: July 6, 2020Date of Patent: March 8, 2022Assignee: Akebia Therapeutics, Inc.Inventors: Christopher M. Lanthier, Boris Gorin, Jan Oudenes, Craig Edward Dixon, Alan Quigbo Lu, James Densmore Copp, John Michael Janusz
-
Patent number: 11065237Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.Type: GrantFiled: February 10, 2020Date of Patent: July 20, 2021Assignee: Akebia Therapeutics, Inc.Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
-
Patent number: 10738010Abstract: Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.Type: GrantFiled: March 13, 2019Date of Patent: August 11, 2020Assignee: Akebia Therapeutics, Inc.Inventors: Christopher M. Lanthier, Boris Gorin, Jan Oudenes, Craig Edward Dixon, Alan Quigbo Lu, James Densmore Copp, John Michael Janusz
-
Patent number: 10729681Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.Type: GrantFiled: August 31, 2018Date of Patent: August 4, 2020Assignee: Akebia Therapeutics, Inc.Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Namal C. Warshakoon